Malignant mesothelioma is a cancer refractory to current therapies. Imatinib Mesylate (STI571, Glivec™) is a selective inhibitor of tyrosine kinases as bcr-abl, c-Kit, c-Fms and Platelet Derived Growth Factor Receptorβ (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for Imatinib in some solid tumors. The aim of this study is to assess whether Imatinib alone or combined with chemotherapeutic agents may be successful for mesothelioma therapy. Cultures from mesothelioma MMP, REN and ISTMES2 cell lines, were treated with Imatinib alone or in combination with chemotherapeutic. We show here that Imatinib induces cytotoxicity and apoptosis selectively on PDGFRβ positive mesothelioma cells, via blockade of receptor phosphorylation and interference with the Akt pathway. Among chemotherapeutics tested in combination, Imatinib synergizes with Gemcitabine and Pemetrexed. We provide a rationale for a novel translational approach to mesothelioma therapy, relying on enhancement of tumor chemosensitivity, via inhibition of Akt.
- Drug Synergism
- Pleural Neoplasm
- Protein Kinase Inhibitors
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.